HIV Vaccine Trial Breaks Ground for Future Research
The results of the worlds first phase 3 HIV vaccine efficacy trial are reported in the March 1 issue of The Journal of Infectious Diseases, now available online. Although the vaccine was ineffective in preventing HIV infection, the trial represents a landmark in the fight against HIV and offers the scientific community a foundation on which to build future trials.
The multi-centered trial, conducted in the United States and the Netherlands and completed in 2003, is described in two papers by the rgp120 HIV Vaccine Study Group, and Peter B. Gilbert and colleagues, which address the vaccine efficacy results and the immunologic responses of the study participants.
The vaccine, produced by VaxGen, was a recombinant construct of the HIV envelope glycoprotein, similar to the type of vaccine used to develop a vaccine for hepatitis B. The vaccine was tested in a double-blind, randomized study of healthy participants who did not use intravenous drugs. The volunteers were men who have sex with men or women at high risk for heterosexual transmission. The vaccine and placebo were given by injection seven times over 30 months and the participants were assessed for risk. At each visit the participants were tested for HIV infection, and for those who were positive, HIV-1 plasma RNA load and CD4 cell counts were monitored on a regular basis for 24 months after the initial diagnosis.
Of the 5,417 volunteers who were enrolled, 368 became infected during the study. The vaccine was found not to be effective in preventing HIV infection; infection rates among those who were given the vaccine and those who were given placebo were 6.7 percent and 7.0 percent, respectively. Of those who became infected during the study, pre-treatment viral loads were similar in the placebo and vaccine groups over their follow-up visits.
During analysis of various subgroups of the study population, a higher, though statistically insignificant, vaccine efficacy was found in the high-risk and the non-white groups. The authors suggested two plausible explanations, one for each group. Those with high-risk behavior may have been exposed frequently to HIV and a primed immune response, probably cellular or humoral, could have worked with the vaccine and caused a greater ability to resist the virus. For the non-white group, the authors suggest that biological differences in immune response or genetic markers of resistance to infection could have made the vaccine more effective.
Also examined in the trial were the immune responses to the vaccine. The vaccine was able to generate antibody responses in virtually all participants, and, in general, those with a higher response had a lower rate of infection than the placebo group. In an editorial accompanying the two papers, Barney Graham and John Mascola of the Vaccine Research Center of the National Institutes for Health commented that more research is needed to be sure whether a high vaccine antibody response is related to a lower incidence of HIV infection. Citing the possible slight vaccine efficacy for non-white and high-risk participants of the trial, they urged that future vaccines be studied in a wide range of racial, ethnic, and diverse risk-level groups. They concluded that the landmark study will inform future studies, and an HIV vaccine will be found only through robust public and private investment as well as a well-informed public and scientific community.
Steve Baragona | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...